Evommune (EVMN) Return on Capital Employed (2025 - 2026)

Evommune (EVMN) posted quarterly Return on Capital Employed of 31.18% for Q1 2026, up 46.36% quarter-over-quarter from 58.12% in Q4 2025.

Evommune (EVMN) Return on Capital Employed (2025 - 2026) Analysis & Trends

Evommune (EVMN) has reported Return on Capital Employed for 2 consecutive years, with 31.18% the latest figure, recorded in Q1 2026.

In Q1 2026, Return on Capital Employed changed N/A year-over-year to 31.18%; the TTM figure through Mar 2026 stood at 31.18% (changed N/A YoY), while the FY2025 annual figure was 61.14%, changed N/A from the prior year.
Return on Capital Employed advanced to 31.18% in Q1 2026 per EVMN's latest filing, from 58.12% in the prior quarter.
Across five years, Return on Capital Employed topped out at 31.18% in Q1 2026 and bottomed at 58.12% in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	20.76%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	10.74%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-55.45%
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	13.68%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-0.20%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	7.88%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	26.09%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-50.93%
10	Evommune	531.53 Mn	330.73 Mn	-	-34.57%

Download Data